)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Alector (ALEC) investor relations material
Alector Study Update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Study Update summary22 Sep, 2025
Pipeline overview and strategy
Focus on developing disease-modifying therapies for neurodegenerative diseases using a three-pronged approach: removing misfolded proteins, replacing deficient proteins, and restoring dysfunctional cells.
Proprietary Electro Brain Carrier (ABC) technology enhances delivery of therapeutics across the blood-brain barrier, enabling delivery of antibodies, enzymes, and siRNA with tailored configurations.
Late-stage pipeline includes progranulin-elevating antibodies for FTD-GRN and Alzheimer's, with additional ABC-enabled programs in preclinical development for Alzheimer's, Parkinson's, Lewy body dementia, Gaucher disease, and other neurodegenerative diseases.
Strong financial position with over $300 million in cash, operational runway into the second half of 2027, and a partnership with GSK including $700M upfront, $1.5B in milestones, 50/50 U.S. profit share, and tiered royalties ex-U.S.
Progranulin-elevating franchise (FTD-GRN and Alzheimer's disease)
Latazimumab/latozinemab (for FTD-GRN) has received breakthrough, fast track, and orphan drug designations; pivotal Phase 3 (INFRONT-3) top-line data expected mid-Q4 2024–2025.
Nivisibart/nivisnebart (for Alzheimer's) is fully enrolled in a Phase 2 trial (PROGRESS-AD), with interim analysis expected in 1H 2026.
Both antibodies increase progranulin by blocking SORT1, restoring levels and showing two- to threefold increases in clinical trials, with normalization of key biomarkers and 48% slowing of clinical progression in FTD-GRN.
INFRONT-3 is a 96-week, global, placebo-controlled trial with co-primary endpoints of clinical progression and plasma progranulin.
Clinical and regulatory updates
FDA requested plasma progranulin as a co-primary endpoint for INFRONT-3; both clinical and biomarker endpoints must meet p<0.05 for success.
Sensitivity analysis will include asymptomatic carriers; further label expansion discussions pending data.
If Phase 3 is positive, company is prepared for rapid BLA filing and commercial manufacturing.
FTD-GRN patient identification strategy?
ABC-enabled siRNA: delivery and efficacy?
AL050's advantage over current GKs ERT?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Alector earnings date
Q3 20255 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. The company is developing AL001, an antibody that targets delta-like ligand 4-Notch to address abnormal signaling triggered by microglia in Alzheimer's disease prevention and slowing in patients with mild cognitive impairment and early-stage Alzheimer's disease; AL101, an anti-TREM2 antibody targeting microglia function that is in Phase IIa clinical trial for the treatment of frontotemporal dementia; AL003, an anti-LINGO monoclonal antibody targeting oligodendrocyte precursor cells for myelination; and AL002 and AL004 for preventing or slowing disease progression in Parkinson's disease. The company was founded in 2013 and is headquartered in South San Francisco, California.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage